Dyadic announces a niimbl coronavirus grant under the white house's american rescue plan

Jupiter, fla., dec. 22, 2021 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on further improving, applying and deploying its proprietary c1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, today announced it is the recipient of one of thirty-two project grants awarded by the national institute for innovation in manufacturing biopharmaceuticals (“niimbl”) funded through the white house's american rescue plan (“arp”).
DYAI Ratings Summary
DYAI Quant Ranking